VARIRID

This brand name is authorized in Nigeria.

Active ingredients

The drug VARIRID contains one active pharmaceutical ingredient (API):

1	Varicella, live attenuated UNII GPV39ZGD8C - VARICELLA-ZOSTER VIRUS STRAIN OKA/MERCK LIVE ANTIGEN
	Natural infection induces a cellular and humoral immune response to the varicella-zoster virus, which can be rapidly detected following infection. IgG, IgM and IgA directed against viral proteins usually appear at the same time that a cellular immune response can be demonstrated, making the relative contribution of humoral and cellular immunity to disease progression difficult to ascertain. Vaccination has been shown to induce both humoral and cell-mediated types of immunity.
	Read more about Varicella, live attenuated

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
A6-100126	Injection	Varirid Vaccine INJ 0.5 mL 0.5 ml	A6-100126 varicella zoster vaccine live 0.5ml/1 dose/vial N/A AN OPALESCENT CAKE AFTER RECONSTITUTION INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION OCTAPHARMA LIMITED CHANGCHUN KEYGEN BIOLOGICAL PRODUCTS CO. LIMITED NO 1118, HUOJU ROAD CHANGCHUN HI-NEW TECHNOLOGY DEVELOPMENT ZONE, JILIN, CHINA 17/07/2023 05/07/2028	17/07/2023

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J07BK01	Varicella, live attenuated	J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BK Varicella zoster vaccines
Discover more medicines within J07BK01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	A6-100126